Evidence map›Paper›PMID 38740564›Full record

ArticlePhysiological reports2024

Evaluation of renal sodium handling in heart failure with preserved ejection fraction: A pilot study.

Adhish Agarwal, Srinivasan Beddhu, Robert Boucher, Veena Rao, Nirupama Ramkumar, Aylin R Rodan, Jacob Fang, Brandi M Wynne, Stavros G Drakos, Thomas Hanff and 2 more

Abstract read
In one paragraph

Article in Physiological reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adhish AgarwalDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-8554-591X
Srinivasan BeddhuDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Robert BoucherDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Veena RaoYale University School of Medicine, New Haven, Connecticut, USA.
Nirupama RamkumarDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Aylin R RodanDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Jacob FangDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Brandi M WynneDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-0861-4245
Stavros G DrakosMedical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Thomas HanffMedical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Alfred K CheungDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
James C FangDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.

Funding

Soluble (pro)renin receptor regulation of kidney fibrosisR01DK133271 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI NIRUPAMA RAMKUMAR · 2023 to 2026
$1.8M
NIDDK NIH HHS R01 DK133271U of U | School of Medicine (University of Utah School of Medicine) 51900436
6 · The paper itself

Abstract

The pathophysiology behind sodium retention in heart failure with preserved ejection fraction (HFpEF) remains poorly understood. We hypothesized that patients with HFpEF have impaired natriuresis and diuresis in response to volume expansion and diuretic challenge, which is associated with renal hypo-responsiveness to endogenous natriuretic peptides. Nine HFpEF patients and five controls received saline infusion (0.25 mL/kg/min for 60 min) followed by intravenous furosemide (20 mg or home dose) 2 h after the infusion. Blood and urine samples were collected at baseline, 2 h after saline infusion, and 2 h after furosemide administration; urinary volumes were recorded. The urinary cyclic guanosine monophosphate (ucGMP)/plasma B-type NP (BNP) ratio was calculated as a measure of renal response to endogenous BNP. Wilcoxon rank-sum test was used to compare the groups. Compared to controls, HFpEF patients had reduced urine output (2480 vs.3541 mL; p = 0.028), lower urinary sodium excretion over 2 h after saline infusion (the percentage of infused sodium excreted 12% vs. 47%; p = 0.003), and a lower baseline ucGMP/plasma BNP ratio (0.7 vs. 7.3 (pmol/mL)/(mg/dL)/(pg/mL); p = 0.014). Patients with HFpEF had impaired natriuretic response to intravenous saline and furosemide administration and lower baseline ucGMP/plasma BNP ratios indicating renal hypo-responsiveness to NPs.

Indexed as

FurosemideHeart FailureKidneyNatriuretic Peptide, BrainSodiumStroke VolumeAgedAged, 80 and overCyclic GMPDiureticsFemaleHumansMaleMiddle AgedNatriuresisPilot ProjectsCyclic GMPDiureticsFurosemideNatriuretic Peptide, BrainSodiumheart failure with preserved ejection fractionrenal sodium handling

Identifiers

PMID38740564
PMCPMC11090885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.